Guselkumab More Effectively Neutralizes Psoriasis-Associated Histologic, Transcriptomic, and Clinical Measures than Ustekinumab

Given the key role of the IL-23/Th17 axis in the pathogenesis of moderate-to-severe plaque psoriasis, several specific inhibitors of the p19 subunit of IL-23 have been approved to treat this chronic inflammatory disease. Clinical data indicate that guselkumab, one such selective IL-23 inhibitor, ach...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Kim, Li, Katherine, Yang, Feifei, Branigan, Patrick, Elloso, M. Merle, Benson, Jacqueline, Orlovsky, Yevgeniya, Chen, Yanqing, Garcet, Sandra, Krueger, James G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AAI 2023
Materias:
Clinical and Translational Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579843/
https://www.ncbi.nlm.nih.gov/pubmed/37071038
http://dx.doi.org/10.4049/immunohorizons.2300003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579843/
https://www.ncbi.nlm.nih.gov/pubmed/37071038
http://dx.doi.org/10.4049/immunohorizons.2300003

Ejemplares similares